Exelixis Inc (EXEL) Stock AnalysisEXELExelixis Inc

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Exelixis Inc is currently priced at $54.45, which is above the average analyst price target of $52, suggesting that it may not be a strong buy at this moment. Additionally, the company has shown solid revenue growth with a 1-year change of +46.45%, but it recently lowered its revenue guidance for 2026 by $50 million due to slower product ramp-up, which poses a risk. The RSI is at 49.468, indicating a neutral momentum, and the stock has a forward P/E of 17.42, which is relatively high compared to its growth prospects. Therefore, while there are positive catalysts such as potential new product approvals, the recent guidance cut and current price levels suggest holding rather than buying.

10 analysts cover EXEL: 6 rate it Buy, 4 Hold and 0 Sell. The average price target is 44.09.